IMMUNEERING ANNOUNCES NEW POTENTIALLY REGISTRATIONAL PHASE 2 TRIAL EVALUATING ATEBIMETINIB WITH CHEMOTHERAPY IN ANAPLASTIC THYROID CANCER

Reuters · 2d ago

Please log in to view news